Erteberel (LY500307)是一种有效的,选择性的雌激素受体β激动剂,EC50为0.66 nM,比作用于雌激素受体α选择性高32倍。
LY500307 is a potent, selective estrogen receptor β agonist with EC50 of 0.66 nM, 32-fold selectivity against estrogen receptor α. Phase 2.
0.01-0.05 mg/kg每天口服处理
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Gangadhara R. Sareddy,et al. Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma. Sci Rep. 2016; 6: 24185. Published online 2016 Apr 29. doi: 10.1038/srep24185.
[2] Bin Yuan,et al. Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer. Oncotarget. 2016 Jul 5; 7(27): 42585–42597. Published online 2016 Jun 14. doi: 10.18632/oncotarget.10018.
分子式 C18H18O3 |
分子量 282.33 |
CAS号 533884-09-2 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 50 mg/mL |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT01874756 | Schizophrenia | Drug: LY500307 150mg|Drug: LY500307 75mg|Drug: Placebo | Indiana University|Eli Lilly and Company | Phase 2 | 2013-06-01 | 2017-03-10 |
NCT01097707 | Benign Prostatic Hyperplasia | Drug: LY500307|Drug: Placebo | Eli Lilly and Company | Phase 2 | 2010-04-01 | 2012-02-10 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们